Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)

In the search for potentially undervalued stocks, we ran a screen based on the theoretical assumption that if P/E is equal to a constant K, growth in EPS estimates should be matched by proportionate growth in price. When they don’t match up, a mispricing may have occurred.

We screened stocks from the healthcare sector for those exhibiting this trend.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the top six stocks mentioned below. Analyst ratings sourced from Zacks Investment Research.

We also created a price-weighted index of the stocks mentioned below, and monitored the performance of the list relative to the S&P 500 index over the last month. To access a complete analysis of this list's recent performance, click here.

Do you think these stocks should be trading higher? Use this list as a starting-off point for your own analysis.

List sorted by market cap.

1. DaVita, Inc. (NYSE:DVA): Provides kidney dialysis services in the United States. Market cap of $6.73B. Over the last 30 days, analyst projected EPS has increased 1.91% (from $4.72 to $4.81), while the price has decreased 0.11% (from $71.58 to $71.50). The stock has gained 11.64% over the last year.

2. Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP): Operates as a specialty healthcare solutions company in the United States. Market cap of $3.55B. Over the last 30 days, analyst projected EPS has increased 2.46% (from $4.47 to $4.58), while the price has decreased 4.27% (from $31.58 to $30.23). The stock has performed poorly over the last month, losing 10.15%.

3. United Therapeutics Corp. (NASDAQ:UTHR): Engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and Internationally. Market cap of $2.50B. Over the last 30 days, analyst projected EPS has increased 4.46% (from $2.69 to $2.81), while the price has decreased 13.76% (from $49.05 to $42.30). The stock has had a couple of great days, gaining 5.3% over the last week.

4. Thoratec Corp. (NASDAQ:THOR): Develops, manufactures, and markets proprietary medical devices used for circulatory support. Market cap of $1.88B. Over the last 30 days, analyst projected EPS has increased 2.05% (from $1.46 to $1.49), while the price has increased 2.04% (from $30.38 to $31.00). It's been a rough couple of days for the stock, losing 6.83% over the last week.

5. Salix Pharmaceuticals Ltd. (NASDAQ:SLXP): Develops, and commercializes prescription drugs for the treatment of gastrointestinal disorders in the United States. Market cap of $1.67B. Over the last 30 days, analyst projected EPS has increased 1.38% (from $2.18 to $2.21), while the price has decreased 14.62% (from $32.70 to $27.92). The stock is a short squeeze candidate, with a short float at 10.42% (equivalent to 7.31 days of average volume). It's been a rough couple of days for the stock, losing 5.59% over the last week.

6. Par Pharmaceutical Companies Inc. (Pending:PRX): Engages in the development, manufacture, and distribution of generic and branded drugs in the United States. Market cap of $986.60M. Over the last 30 days, analyst projected EPS has increased 3.15% (from $3.17 to $3.27), while the price has increased 2.98% (from $27.18 to $27.99). It's been a rough couple of days for the stock, losing 8.87% over the last week.

7. Acorda Therapeutics, Inc. (NASDAQ:ACOR): Involves in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury, and other nervous system disorders. Market cap of $985.55M. Over the last 30 days, analyst projected EPS has increased 10.0% (from $0.80 to $0.88), while the price has increased 5.38% (from $22.86 to $24.09). The stock is a short squeeze candidate, with a short float at 11.09% (equivalent to 7.91 days of average volume). The stock has lost 23.94% over the last year.

8. Luminex Corporation (NASDAQ:LMNX): Develops, manufactures, and sells proprietary biological testing technologies and products for the life sciences and diagnostic industries in the United States. Market cap of $930.38M. Over the last 30 days, analyst projected EPS has increased 20.0% (from $0.30 to $0.36), while the price has increased 14.54% (from $18.50 to $21.19). The stock is a short squeeze candidate, with a short float at 6.16% (equivalent to 9.08 days of average volume). The stock has had a good month, gaining 11.79%.

9. Momenta Pharmaceuticals Inc. (NASDAQ:MNTA): Specializes in the in the characterization and process engineering of complex molecules. Market cap of $838.16M. Over the last 30 days, analyst projected EPS has increased 30.79% (from $3.15 to $4.12), while the price has increased 6.44% (from $15.07 to $16.04). The stock is a short squeeze candidate, with a short float at 16.83% (equivalent to 10.89 days of average volume). It's been a rough couple of days for the stock, losing 5.21% over the last week.

10. Kindred Healthcare Inc. (NYSE:KND): Operates as a healthcare services company in the United States. Market cap of $598.74M. Over the last 30 days, analyst projected EPS has increased 2.22% (from $1.80 to $1.84), while the price has increased 0.53% (from $11.29 to $11.35). It's been a rough couple of days for the stock, losing 10.3% over the last week.

11. Simcere Pharmaceutical Group. (NYSE:SCR): Develops, manufactures, and markets branded generic and proprietary pharmaceuticals in China. Market cap of $517.44M. Over the last 30 days, analyst projected EPS has increased 5.56% (from $0.54 to $0.57), while the price has decreased 1.37% (from $9.50 to $9.37). The stock has had a couple of great days, gaining 9.71% over the last week.

12. LHC Group, Inc. (NASDAQ:LHCG): Provides post-acute healthcare services primarily to Medicare beneficiaries in rural markets in the United States. Market cap of $342.17M. Over the last 30 days, analyst projected EPS has increased 0.93% (from $2.15 to $2.17), while the price has decreased 2.94% (from $18.39 to $17.85). The stock is a short squeeze candidate, with a short float at 10.09% (equivalent to 7.25 days of average volume). It's been a rough couple of days for the stock, losing 9.18% over the last week.

*EPS and price data sourced from Yahoo! Finance, all other data sourced from Finviz.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.